Role of membrane potential in the accumulation of quaternized ellipticines by human tumor cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 1018-1025

  Vistica, David T ^a   Kenney, Susan ^a   Hursey, Miriam ^a   Boyd, Michael R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 METHOXY N2 METHYLELLIPTICINIUM ACETATE; ANTINEOPLASTIC AGENT; BIS(1,3 DIBUTYLBARBITURIC ACID)TRIMETHINE OXONOL; ELLIPTICINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG ACCUMULATION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; KIDNEY CARCINOMA; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; OVARY CARCINOMA; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR LOCALIZATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG RESISTANCE; ELLIPTICINES; HUMANS; MEMBRANE POTENTIALS; POTASSIUM; TUMOR CELLS, CULTURED;

EID: 0030440926     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. ACKERMAN, K. E. O. AND WILKSTROM, M. K. F.: Safranine as a probe of the mitochondrial membrane potential. FEBS Lett. 68: 191-197, 1976.
2. ACTON, E., NARAYANAN, V. L, RISBOOD, P. A., SHOEMAKER, R. H., VISTICA, D. T. AND BOYD, M. R.: Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J. Med. Chem. 37: 2185-2189, 1994.
3. BASHFORD, C. L. AND PASTERNAK, C. A.: Plasma membrane potential of Lettre cells does not depend on cation gradients but on pumps. J. Membr. Biol. 79: 275-284, 1984.
4. BASHFORD, C. L. AND SMITH, J. C.: The use of optical probes to monitor membrane potential. Methods Enzymol. 60: 569-585, 1979.
5. BOYD, M. R.: Status of the NCI preclinical anticancer drug discovery screen: Implications for selection of new agents for clinical trial. In Cancer: Principles and Practice of Oncology Updates, ed. by V. T. DeVita, S. Hellman and S. A. Rosenberg, vol. 3, no. 10, pp. 1-12, Lippincott, Philadelphia, 1989.
6. BOYD, M. R.: The future of new drug development. In Current Therapy in Oncology, ed. by J. E. Niederhuber, pp. 11-22, B. C. Decker, Philadelphia, 1993.
7. BRADFORD, M. M.: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
8. CHARCOSSET, J., JACQUE MIN-SABLON, A. AND LEPECQ, J.: Effect of membrane potential on the cellular uptake of 2-N-methyl-ellipticinium by L1210 cells. Biochem. Pharmacol. 33: 2271-2275, 1984.
9. CIVITELLI, R., REID, I. R., HALSTEAD, L. R., AVIOLI, L. V. AND HRUSKA, K. A.: Membrane potential and cation content of osteoblast-like cells (UMR 106) assessed by fluorescent dyes. J. Cell Physiol. 131: 434-441, 1987.
10. DUPONT, J., DODIN, G. AND SCHWALLER, M. A.: Interactions between ellipticine derivatives and the mitochondrial respiratory chain. Plant Sci. Lett. 54: 109-115, 1988.
11. GANZ, M. B., BOYARSKY, G., BORON, W. F. AND STERZEL, R. B.: Effects of angiotensin II and vasopressin on intracellular pH of glomerular mesangial cells. Am. J. Physiol. 254: F787-F794, 1988.
12. 2-methylellipticinium acetate in human brain and non-brain tumor cell lines. Biochem. Pharmacol. 49: 23-32, 1995.
13. RANSOM, B. R. AND CARLINI, W. G.: Electrophysiological properties of astrocytes. In Astrocytes: Biochemistry, Physiology and Pharmacology of Astrocytes, ed. by S. Fedorof and A. Vernadakis, pp. 1-49, Academic Press, Orlando, FL, 1986.
14. SAUTEREAU, A. AND TROMBE, M.: Electric transmembrane potential mutation and resistance to the cationic and amphiphilic antitumoral drugs derived from pyridocarbazole, 2-N-methylellipticinium and 2-N-methyl-9-hydroxyellipticinium, in Streptococcus pneumoniae. J. Gen. Microbiol. 132: 2637-2641, 1986.
15. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISTICA, D., WARREN, J., BOKESCH, H., KENNEY, S. AND BOYD, M.: New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. 82: 1107-1112, 1990.
16. SMITH, J. C.: Potential-sensitive molecular probes in membranes of bioenergetic relevance. Biochim. Biophys. Acta 1016: 1-28, 1990.
17. SOKAL, R. AND ROHLF, R.: In Biometry, ed. by R. Emerson, D. Kennedy, R. Park, G. Beadle and D. Whitaker, Correlation, pp. 494-548, W. H. Freeman, New York, 1969.
18. STINSON, S. F., ALLEY, M. C., KOPP, W. C., FIEBIG, H. H., MULLENDORE, L., PITTMAN, A., KENNEY, S., KELLER, J. AND BOYD, M. R.: Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res. 12: 1035-1054, 1992.
19. SUREAU, F., MOREAU, F., MILLOT, J., MANFAIT, M., ALLARD, B., AUBARD, J. AND SCHWALLER, M.: Microspectrofluorometry of the protonation state of ellipticine, an antitumor alkaloid in single cells. Biophys. J. 65: 1767-1774, 1993.
20. TROMBE, M., LANEELLE, G. AND SICARD, A.: Characterization of a Streptococcus pneumoniae mutant with altered electric transmembrane potential. J. Bacteriol. 158: 1109-1114, 1984.
21. VISTICA, D. T., KENNEY, S., HURSEY, M. AND BOYD, M. R.: Cellular uptake as a determinant of cytotoxicity of quaternized ellipticines to human brain tumor cells. Biochem. Biophys. Res. Commun. 200: 1762-1768, 1994.
22. WOODBURY, J. W.: The cell membrane: Ion fluxes and the genesis of the resting potential. In Physiology and Biophysics, ed. by A. Howell and S. Fulton, XX, pp. 1-46, W. B. Saunders, Philadelphia, 1982.